Hinova Pharmaceuticals released its 2026 interim report, showing total operating revenue of 54.9706 million yuan, net profit attributable to the parent company of negative 56.2181 million yuan, and net cash flow from operating activities of negative 46.3941 million yuan. The company's latest asset-liability ratio is 20.86%, gross margin is 97.34%, return on equity is negative 5.58%, and diluted earnings per share is negative 0.57 yuan. The number of shareholders is 7,146, and the top ten shareholders hold 37.71% of total share capital.
Hinova Pharmaceuticals Inc. ACompany reports net loss of 56.2181 million yuan in interim report.
